Health Technology Assessment
Health technology assessment (HTA) is the systematic evaluation of health technologies—drugs, devices, diagnostics, procedures, and increasingly digital tools and public-health programmes—to inform decisions about whether and how they should be used and paid for.
10 frameworks, from 1970 to today · Health Economics · Economics
- Cost-Effectiveness Analysis 1970-Present
- Cost-Utility Analysis 1980-Present
- Decision-Analytic Modelling 1990-Present
- Systematic review 1990-Present
- Budget Impact Analysis 1995-Present
- Threshold-Based Appraisal 1999-Present
- Multiple-criteria decision analysis 2000-Present
- Value-Based Pricing 2000-Present
- Extended Value and Severity-Weighted Assessment 2005-Present
- Real world evidence 2010-Present
Overview
Health technology assessment (HTA) is the systematic evaluation of health technologies—drugs, devices, diagnostics, procedures, and increasingly digital tools and public-health programmes—to inform decisions about whether and how they should be used and paid for. Its practitioners ask a deceptively simple question: given finite budgets, does this technology deliver enough benefit to justify its cost, and if so, for whom? The stakes are concrete. When a national insurer decides whether to cover a new cancer drug, or a hospital decides whether to adopt a surgical robot, someone is deciding how a fixed pool of money becomes health. HTA is the machinery that has grown up to make those decisions defensible rather than arbitrary.
From Clinical Trials to Economic Evaluation: The Postwar Roots
The intellectual foundations lie in the mid-twentieth century, when two streams converged. One was the randomised controlled trial (RCT), which by the 1960s had become the gold standard for establishing whether a treatment works at all. The other was welfare economics, which supplied the idea that public spending should be judged by the value of what it buys relative to its opportunity cost—the health forgone elsewhere when money is spent here.
The pivotal figure was Alan Williams, a British health economist who in the 1970s and 1980s argued that health services should be evaluated in terms of cost per unit of health gain, not cost per case or per bed-day. His work helped establish the discipline of health economics in Britain and gave HTA its central metric. In the United States, the Office of Technology Assessment (OTA), created by Congress in 1972, pioneered the systematic appraisal of medical technologies for policymakers, though its remit was broader than economics and it was abolished in 1995. The term "health technology assessment" itself gained currency in the 1980s, as European governments began building formal bodies to advise on coverage.
The Cost-Effectiveness Toolkit
The core analytic method that emerged is cost-effectiveness analysis (CEA): comparing the incremental cost of a technology with its incremental health benefit, usually expressed as cost per life-year gained or per case detected. Its logic is comparative—a technology is judged against the best available alternative, not against doing nothing—and its output is a ratio, the incremental cost-effectiveness ratio (ICER), which states how much extra money buys one extra unit of health.
A crucial refinement was cost-utility analysis (CUA), which measures benefit in quality-adjusted life-years (QALYs)1. A QALY combines length of life with quality of life on a single scale: one year in perfect health equals 1.0, a year with moderate disability might equal 0.62. The QALY was developed in the 1970s and 1980s by researchers including Milton Weinstein and George Torrance, building on earlier work on health-status measurement. Its appeal is that it allows comparison across entirely different diseases—a hip replacement and a cancer drug can be judged on the same yardstick. The QALY remains the dominant outcome measure in HTA, though it has always attracted criticism for how it values different kinds of health states and different people.
Decision-Analytic Modelling: Simulating the Future
Trials are short and narrow; decisions are long and broad. Decision-analytic modelling filled the gap. Rather than relying only on observed trial data, analysts built mathematical models—decision trees, Markov models, and later discrete-event simulations—that projected costs and outcomes over a lifetime or a budget period, synthesising evidence from many sources. A Markov model, for instance, represents a patient moving among health states (well, sick, dead) with probabilities drawn from trials and epidemiology, and accumulates costs and QALYs over time. This made it possible to evaluate technologies before long-term data existed, and to conduct sensitivity analysis—testing how conclusions change when assumptions vary. The approach was codified in influential textbooks and guidelines from the 1990s onward, notably the work of Michael Drummond and colleagues, whose Methods for the Economic Evaluation of Health Care Programmes became a standard reference.
Evidence Synthesis and the Systematic Review
HTA rests on evidence, and the evidence base is vast and uneven. Systematic review and evidence synthesis became the method for assembling it: a pre-specified, reproducible search and appraisal of all relevant studies, often culminating in a meta-analysis that pools results statistically3. The Cochrane Collaboration, founded in 1993, institutionalised this approach for health care, and HTA bodies adopted it as a required first step. The logic is that a coverage decision should rest on the totality of evidence, not on a single favourable trial—and that the process of finding and weighing evidence should itself be transparent and replicable.
National Bodies and the Rise of Formal Appraisal
The 1990s and 2000s saw HTA institutionalised. The most influential example is the UK's National Institute for Health and Care Excellence (NICE), established in 1999. NICE introduced a formal, published appraisal process with a cost-effectiveness threshold: technologies were generally recommended if their ICER fell below a stated range (initially around £20,000–£30,000 per QALY). The threshold made the opportunity-cost logic explicit—below it, a technology was deemed worth buying; above it, the health forgone elsewhere outweighed the gain. NICE's model spread: Australia's Pharmaceutical Benefits Advisory Committee had pioneered formal economic evaluation for drugs in the early 1990s, and Canada, Germany, and many other countries built their own bodies with varying methods and thresholds.
Value-based pricing and threshold appraisal grew from this. The idea is that a technology's price should reflect the value it delivers—its health gain relative to cost—rather than what the market will bear. Thresholds operationalise this: they define what the system is willing to pay per QALY. The approach is powerful but contested, because the "right" threshold depends on the marginal productivity of the health system, which is hard to measure and varies by context.
Budget Impact and the Affordability Question
Cost-effectiveness asks whether a technology is worth its price; budget impact analysis asks whether the system can afford it this year. A technology can be highly cost-effective and still blow a hole in a fixed annual budget if it is expensive per patient and used widely. Budget impact analysis projects the financial consequences of adoption over a short horizon, typically one to five years, accounting for uptake rates and offsets. It became a standard companion to cost-effectiveness in reimbursement dossiers, particularly for pharmaceuticals, because payers must plan cash flow as well as value.
Multi-Criteria Decision Analysis and the Broadening of Value
Not everything that matters fits into a QALY. Multi-criteria decision analysis (MCDA) emerged as a structured way to weigh multiple dimensions—severity of disease, unmet need, equity, innovation, budget impact—explicitly rather than implicitly4. Practitioners assign scores and weights to criteria and combine them into a ranking. MCDA has been used in several HTA contexts, though its uptake has been uneven; critics note that weights are themselves value judgements, and that the method can obscure as much as it clarifies if poorly applied.
A related development is extended value and severity-weighted assessment. Some systems give extra weight to health gains for people with severe conditions, or to technologies addressing unmet need, rather than treating all QALYs as equal. The Netherlands and Norway, among others, have experimented with severity weighting, and debates about "extended value" ask whether HTA should recognise dimensions beyond health gain—such as equity, caregiver burden, or the value of hope. These debates are live and unresolved; the QALY remains the anchor, but its monopoly is contested.
Real-World Evidence and the Data Revolution
Trials are artificial. Real-world evidence (RWE)—data from registries, electronic health records, claims databases, and observational studies—offers a picture of how technologies perform in ordinary practice, among patients often excluded from trials. HTA bodies have increasingly accepted RWE for specific purposes: confirming long-term safety, evaluating technologies in rare diseases where trials are impractical, and monitoring performance after coverage. The challenge is causal inference: observational data are confounded, and HTA must judge whether an RWE study credibly identifies a treatment effect. Methods from econometrics and epidemiology—propensity scoring, instrumental variables, difference-in-differences—have migrated into HTA for this reason, and regulatory agencies alongside HTA bodies have issued guidance on when RWE is fit for purpose.
The Present: Institutionalised, Contested, Expanding
Today HTA is a global enterprise. Nearly every high-income country has a formal body, and middle-income countries are building them. Methods have converged around cost-effectiveness and cost-utility analysis, decision-analytic modelling, systematic review, and budget impact, with national variation in thresholds, weighting, and process. The field's open questions are substantive: how to value health states and whose preferences count; whether thresholds should be explicit and how to set them; how to incorporate equity and severity; how to handle uncertainty and rare diseases; and how to integrate real-world evidence credibly. The machinery built over five decades is now the ordinary language of coverage decisions—and the arguments about what it should measure are the field's continuing history.
References
- Cost–utility analysis, Wikipedia
- Quality-adjusted life year, Wikipedia
- Systematic review, Wikipedia
- Multiple-criteria decision analysis, Wikipedia
The frameworks of Health Technology Assessment
Each framework is a way of working the field has used: when it held, and the question it answers.
- 1970-Present
Cost-Effectiveness Analysis
Is this technology worth its cost in health gained?
- 1980-Present
Cost-Utility Analysis
How much health gain per pound does a treatment buy?
- 1990-Present
Decision-Analytic Modelling
What will costs and outcomes be over a lifetime?
- 1990-Present
- 1995-Present
Budget Impact Analysis
Can the health system afford this technology this year?
- 1999-Present
- 2000-Present
Multiple-criteria decision analysis
How should many competing criteria be weighed together?
- 2000-Present
- 2005-Present
Extended Value and Severity-Weighted Assessment
Should health gains count more for the severely ill?
- 2010-Present
How the ideas connect
Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.
Cost-Utility Analysis grew out of Cost-Effectiveness Analysis
Cost-utility analysis grew out of cost-effectiveness analysis by replacing the natural-unit health outcome with the quality-adjusted life-year, allowing comparison across diseases. Weinstein and Torrance developed the QALY in the 1970s and 1980s as a refinement of the cost-per-health-gain logic.
Carried by Milton Weinstein; George Torrance.
Threshold-Based Appraisal grew out of Cost-Effectiveness Analysis
Threshold-based appraisal operationalised cost-effectiveness analysis by setting a stated willingness-to-pay per QALY below which technologies were recommended. NICE's 1999 appraisal process made the ICER threshold the explicit decision rule.
Carried by NICE.
Threshold-Based Appraisal grew out of Cost-Utility Analysis
The cost-per-QALY threshold used in formal appraisal depends on cost-utility analysis to express benefits on a common scale. NICE's £20,000–£30,000 per QALY range applied the QALY metric as the basis for coverage decisions.
Carried by NICE.
Decision-Analytic Modelling grew out of Cost-Effectiveness Analysis
Decision-analytic modelling extended cost-effectiveness analysis by projecting costs and outcomes beyond trial horizons using decision trees and Markov models. It supplied the long-term and probabilistic estimates that the ICER framework required but trials could not provide.
Carried by Michael Drummond; Methods for the Economic Evaluation of Health Care Programmes (1987).
Budget Impact Analysis grew out of Cost-Effectiveness Analysis
Budget impact analysis emerged as a companion to cost-effectiveness analysis, asking whether an affordable technology can be financed within a fixed annual budget. It took the cost side of CEA and projected short-term financial consequences for payers.
Decision-Analytic Modelling grew out of Cost-Utility Analysis
Markov and simulation models were built specifically to accumulate QALYs over a lifetime, making cost-utility analysis computable when long-term data were absent. The QALY outcome measure became the standard output of decision-analytic models in HTA.
Carried by Michael Drummond.
Multiple-criteria decision analysis reacted against Cost-Utility Analysis
Multi-criteria decision analysis arose partly as a response to the QALY's monopoly, arguing that dimensions such as severity, equity and unmet need should be weighted explicitly rather than collapsed into a single cost-per-QALY ratio. It defined itself against the single-outcome logic of cost-utility analysis.
Extended Value and Severity-Weighted Assessment reacted against Cost-Utility Analysis
Extended value and severity-weighted assessment reacted against treating all QALYs as equal, giving extra weight to health gains for people with severe conditions or unmet need. The Netherlands and Norway experimented with severity weighting as a correction to the standard QALY.
Decision-Analytic Modelling influenced by Systematic review
Decision-analytic models synthesise evidence from many sources, and systematic review supplied the reproducible method for assembling and appraising that evidence base. HTA guidelines required systematic review as the first step feeding model parameters.
Carried by Cochrane Collaboration.
Value-Based Pricing grew out of Threshold-Based Appraisal
Value-based pricing grew from threshold appraisal by turning the willingness-to-pay per QALY into a basis for setting price rather than only for coverage. The threshold defines what the system will pay per unit of health gain, and value-based pricing applies that to the price itself.
Extended Value and Severity-Weighted Assessment influenced by Multiple-criteria decision analysis
The multi-criteria critique that not everything fits into a QALY fed into extended value assessment, which recognises dimensions beyond health gain such as equity and caregiver burden. Both movements sought to broaden the value basis of HTA beyond the single QALY.
Beyond the field
Where Health Technology Assessment's ideas came from in other fields, and what they led to there: the strongest 12 of 43 links.
Cost-Effectiveness Analysis influenced by Cost-Benefit Analysis in Impact Evaluation
Cost-benefit analysis supplied the basic framework of comparing costs and consequences in commensurate terms that health cost-effectiveness analysis adapted by using natural health-effect units instead of dollars.
Cost-Effectiveness Analysis influenced by Cost–benefit analysis in Welfare Economics
Welfare-economic cost-benefit analysis provided the theoretical apparatus of comparing streams of costs and benefits that cost-effectiveness analysis in health reworked with health-outcome measures.
Cost-Utility Analysis influenced Burden of Disease and Cost-Effectiveness Priority Setting in Health Policy
Cost-utility analysis, with the quality-adjusted life year, was the direct methodological basis for the DALY-based burden of disease and priority-setting framework.
Carried by Christopher Murray.
Cost-Utility Analysis grew out of Cost-effectiveness analysis in Health Economics
Cost-utility analysis grew directly out of cost-effectiveness analysis by replacing natural effect units with quality-adjusted life years as the outcome metric.
Cost-Utility Analysis grew out of Cost-Effectiveness Analysis in Comparative Effectiveness Research
Cost-utility analysis is a direct refinement of cost-effectiveness analysis, substituting utility-weighted health states for single natural effect measures.
Decision-Analytic Modelling grew out of Decision analysis in Clinical Reasoning
Decision analysis in clinical reasoning supplied the tree-building and expected-utility methods that decision-analytic modelling in HTA generalised to technology assessment.
Decision-Analytic Modelling grew out of Decision Analysis in Clinical Decision Science
Decision-analytic modelling in HTA is a direct extension of clinical decision analysis, applying decision trees and expected-value calculations to population-level technology appraisal.
Cost-Effectiveness Analysis grew out of Cost–benefit analysis in Environmental Economics
Cost-effectiveness analysis in health technology assessment is a branch of cost-benefit analysis, retaining its cost accounting but measuring outcomes in natural units such as life-years rather than money.
Cost-Effectiveness Analysis influenced Comparative Effectiveness Research in Health Services Research
Cost-effectiveness analysis as developed in health technology assessment provided the economic evaluation methods that comparative effectiveness research used to compare interventions. The techniques passed into the later programme.
Cost-Effectiveness Analysis influenced Health Technology Assessment in Social And Administrative Pharmacy
Cost-effectiveness analysis supplied health technology assessment with its core comparative metric of cost per unit of health outcome. HTA reports are routinely built on cost-effectiveness analysis.
Cost-Utility Analysis influenced Distributional and equity analysis in Health Policy Evaluation
Cost-utility analysis with QALYs supplied the outcome metric that equity analysts weighted and disaggregated to examine distributional fairness.
Cost-Utility Analysis influenced Distributional cost-effectiveness analysis in Health Policy Evaluation
Distributional cost-effectiveness analysis uses cost-utility analysis as its underlying efficiency metric, measuring health gains in QALYs and then adding distributional weights. The QALY-based cost-utility framework supplies the outcome measure that DCEA redistributes across groups.
Carried by Richard Cookson; Miqdad Asaria.

Health Technology Assessment is a planet in Nousfarer
Its city has a tower for each of these 10 frameworks. Land, walk in, and climb one concept at a time.
Land on Health Technology AssessmentRelated fields
Fields its ideas are linked to
- Health Policy Evaluation 7 links
- Health Economics 4 links
- Health Services Research 4 links
- Impact Evaluation 3 links
- Comparative Effectiveness Research 2 links
- Operations Research 2 links
- Managerial Decision Making 2 links
- Clinical Decision Science 2 links
- Clinical Reasoning 2 links
- Welfare Economics 2 links
- Decision And Risk Analysis 2 links
- Environmental Economics 1 link
More in Health Economics
- Health Capital And Demand For Health
- Health Economics
- Health Insurance
- Health Policy Evaluation
- Healthcare Markets
- Pharmaceutical Economics
See where Health Technology Assessment sits on the Map of Human Knowledge